Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 506 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR First-Line 177Lu-Dotatate Plus Octreotide LAR Significantly Extends PFS in Patients with... June 13, 2024 ΚΑΡΚΙΝΟΣ ΤΟΥ ΝΕΦΡΟΥ February 10, 2019 Heartburn Medications Pulled From Shelves Because They May Cause Cancer January 13, 2020 What’s at the Root of Ovarian Cancer? New Study May Have... April 24, 2025 Load more HOT NEWS The 10-year cancer plan: is improving cancer survival still a priority... The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic... 37-Year-Old Mom Breaks American Marathon Record Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of...
